Another artificial intelligence (AI) assistant has joined the medical imaging space, following the US Food and Drug Administration’s (FDA) clearance of Sonio’s quality control software.

Sonio Detect is a Software as a Service (SaaS) designed to support practitioners during foetal ultrasounds. The software is manufacturer agnostic and helps quality control ultrasound exams.  With the tech, healthcare professionals will have improved efficiency in detecting anatomy, such as the presence of heart and brain structures, and help support other important foetal imaging quality criteria.

According to the Paris, France-based company, the prenatal screening solution has high accuracy rate in identifying correct labels, views, and quality criteria regardless of patient demographic or device manufacturer. Sonio Detect has been validated on over 17,000 ultrasound images.

Sonio’s other lead product is Sonio Diagnostics – a CE-marked device which the company says helps guide practitioners through 250 syndromes and 700 anomalies that can be presented during a scan.

The femtech developer, which raised $14m in Series A financing in July, has joined a wave of companies exploring AI use in medical imaging. AI in medical imaging is one of the fastest growing uses of the technology in healthcare. It can increase the throughput of screening and diagnosis by automating several processes in the imaging workflow.

Sonio’s CEO and co-founder, Cecile Brosset said: “Bringing the first easy to use, manufacturer agnostic (GE, Samsung and Canon) and efficient quality control solution to all OBGYNs, MFMs and Sonographers, we believe better screening will lead to better detection of potential anomalies or reassurance to provide better maternal care.”